Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood ...
Learn how to leverage the power of multiomics without the steep learning curve of bioinformatics. With intuitive interfaces and powerful analytical tools, you can unlock comprehensive biological ...
Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced the launch of BioInsight, a ...
DNA sequencing company Illumina and Nashville Biosciences, a wholly owned subsidiary of Nashville, Tenn.-based Vanderbilt University Medical Center, are working with biopharmaceutical company Amgen to ...
GUILDFORD, SURREY / ACCESS Newswire / January 29, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...
SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback